Nonetheless, engineered to improve tumor selectivity, bispecific targeting dual agents, such as GD2 × B7-H3, address the challenge of off-tumor toxicities typical in anti-GD2 therapies through restriction of T-cell engagement to cells expressing both markers, hence reducing peripheral nerve binding and enhancing therapeutic index [105]. This evidence concerns the gene CD276 and neoplasm.